Silver Book Fact

Mean 5-Year Cumulative Total Medical Costs Per Medically Managed (No AVR) Severe AS Patient

Clark M, Arnold S, Duhay F, Thompson A, et al. Five-Year Clinical and Economic Outcomes Among Patients with Medically Managed Severe Aortic Stenosis: Results from a Medicare claims analysis. Circulation: Cardiovascular Quality and Outcomes. 2012; 5(5). http://circoutcomes.ahajournals.org/content/5/5/697

Reference

Title
Five-Year Clinical and Economic Outcomes Among Patients with Medically Managed Severe Aortic Stenosis: Results from a Medicare claims analysis
Publication
Circulation: Cardiovascular Quality and Outcomes
Publication Date
2012
Authors
Clark M, Arnold S, Duhay F, Thompson A, et al.
Volume & Issue
Volume 5, Issue 5
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • 2016 prevalence of Americans 65+ who had AVD
    In 2016, an estimated 5.2 million U.S. adults ages 65+ had aortic valve disease (AVD).   Note: Alliance for Aging Research generated statistic, based on 2005 percentage prevalence estimates by Bach et al. 2007  
  • All-cause mortality for aortic valve disorders
    In 2014, all-cause mortality for aortic valve disorders was 34,408 in the U.S.  
  • Lifespan of Medicare patients with sSAS who do not undergo treatment
    Medicare patients with severe symptomatic aortic stenosis (sSAS) who do not undergo treatment have an average lifespan of 1.8 years.  
  • 1 and 6-month mortality rates without treatment for sSAS
    Waiting for treatment for severe symptomatic aortic stenosis (sSAS) can be deadly, with 1-month mortality at 3.7% and 6-month mortality at 11.6% (measured from the time intervention was recommended).  
  • Moderate or severe aortic valve disease is present in 4.2% to 10.7% of the population ages 65 and older.